DK0888330T3 - Fremgangsmåder til behandling eller forebyggelse af interstitiel cystitis - Google Patents

Fremgangsmåder til behandling eller forebyggelse af interstitiel cystitis

Info

Publication number
DK0888330T3
DK0888330T3 DK97914868T DK97914868T DK0888330T3 DK 0888330 T3 DK0888330 T3 DK 0888330T3 DK 97914868 T DK97914868 T DK 97914868T DK 97914868 T DK97914868 T DK 97914868T DK 0888330 T3 DK0888330 T3 DK 0888330T3
Authority
DK
Denmark
Prior art keywords
interstitial cystitis
treating
methods
preventing interstitial
preventing
Prior art date
Application number
DK97914868T
Other languages
Danish (da)
English (en)
Inventor
Smriti Iyengar
Mark A Muhlhauser
Karl B Thor
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0888330T3 publication Critical patent/DK0888330T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Threshing Machine Elements (AREA)
  • Processing Of Meat And Fish (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nozzles (AREA)
  • Heat Treatment Of Articles (AREA)
  • Transplanting Machines (AREA)
  • Pistons, Piston Rings, And Cylinders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Steroid Compounds (AREA)
DK97914868T 1996-03-11 1997-03-07 Fremgangsmåder til behandling eller forebyggelse af interstitiel cystitis DK0888330T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1315796P 1996-03-11 1996-03-11
PCT/US1997/003410 WO1997033880A1 (en) 1996-03-11 1997-03-07 Methods of treating or preventing interstitial cystitis

Publications (1)

Publication Number Publication Date
DK0888330T3 true DK0888330T3 (da) 2003-09-01

Family

ID=21758595

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97914868T DK0888330T3 (da) 1996-03-11 1997-03-07 Fremgangsmåder til behandling eller forebyggelse af interstitiel cystitis

Country Status (23)

Country Link
EP (1) EP0888330B1 (de)
JP (1) JP2000506863A (de)
KR (1) KR19990087671A (de)
CN (1) CN1217721A (de)
AT (1) ATE239467T1 (de)
AU (1) AU730448B2 (de)
BR (1) BR9708027A (de)
CA (1) CA2250288A1 (de)
CZ (1) CZ287798A3 (de)
DE (1) DE69721747T2 (de)
DK (1) DK0888330T3 (de)
EA (1) EA001325B1 (de)
ES (1) ES2197993T3 (de)
HU (1) HUP9902884A3 (de)
IL (1) IL126159A (de)
NO (1) NO984160L (de)
NZ (1) NZ331811A (de)
PL (1) PL328959A1 (de)
PT (1) PT888330E (de)
RO (1) RO117296B1 (de)
UA (1) UA62926C2 (de)
WO (1) WO1997033880A1 (de)
YU (1) YU39598A (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2344057C (en) 1998-09-15 2008-11-18 Eli Lilly And Company Treatment of persistent pain
EP1383495A1 (de) * 2001-03-29 2004-01-28 Eli Lilly And Company Duloxetine zur verminderung von hitzewallungen
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
DE10247689A1 (de) * 2002-10-12 2004-04-22 Martin Rahe Implantat in der Harnblase
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
EP1904039A2 (de) * 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Kontrollierte duloxetin-dosierungsfreisetzungsformel
EP2099492B1 (de) * 2006-12-27 2013-06-05 LEK Pharmaceuticals d.d. Duloxetin-zusammensetzung
EP1938840A1 (de) * 2006-12-27 2008-07-02 LEK Pharmaceuticals D.D. Duloxetinzusammensetzung
EP2018860A1 (de) * 2007-07-16 2009-01-28 LEK Pharmaceuticals D.D. Duloxetinzusammensetzung
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
RU2719929C1 (ru) * 2018-12-17 2020-04-23 Юрий Анатольевич Игнашов Способ выбора лечения женщин с синдромом болезненного мочевого пузыря

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574474A (en) * 1897-01-05 Course-indicating apparatus
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence

Also Published As

Publication number Publication date
NO984160D0 (no) 1998-09-10
CA2250288A1 (en) 1997-09-18
DE69721747T2 (de) 2004-04-01
EP0888330A1 (de) 1999-01-07
IL126159A (en) 2003-01-12
EP0888330A4 (de) 1999-04-07
CN1217721A (zh) 1999-05-26
HUP9902884A2 (en) 2000-07-28
EA199800816A1 (ru) 1999-02-25
RO117296B1 (ro) 2002-01-30
AU730448B2 (en) 2001-03-08
ATE239467T1 (de) 2003-05-15
AU2196297A (en) 1997-10-01
NZ331811A (en) 2001-04-27
DE69721747D1 (de) 2003-06-12
EA001325B1 (ru) 2001-02-26
UA62926C2 (en) 2004-01-15
PT888330E (pt) 2003-09-30
PL328959A1 (en) 1999-03-01
CZ287798A3 (cs) 1999-05-12
IL126159A0 (en) 1999-05-09
JP2000506863A (ja) 2000-06-06
NO984160L (no) 1998-09-10
WO1997033880A1 (en) 1997-09-18
EP0888330B1 (de) 2003-05-07
KR19990087671A (ko) 1999-12-27
HUP9902884A3 (en) 2000-12-28
YU39598A (sh) 1999-09-27
ES2197993T3 (es) 2004-01-16
BR9708027A (pt) 1999-08-03

Similar Documents

Publication Publication Date Title
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
ATE413386T1 (de) Ppar-gamma modulatoren
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DK0867184T3 (da) Anvendelse af tiagabin til behandling af søvnforstyrrelser
BR0111601A (pt) Método para o tratamento de doença cardiovascular
DK0888330T3 (da) Fremgangsmåder til behandling eller forebyggelse af interstitiel cystitis
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DK1291018T3 (da) Phosphonatananaloger til mannose-6phosphat og deres anvendelse i behandlingen af sår og fibrotiske lidelser
NO984760L (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
DE69924979D1 (de) Behandlung von chronischen schmerzen
EA199800819A1 (ru) Способ лечения биполярного расстройства
DK0984787T3 (da) Anvendelse af lavmolekylære hepariner til forebyggelse og behandling af hjerneødemer
DK1140119T3 (da) Anvendelse af heparin med lav molekylvægt til forebyggelse og/eller behandling af motorneuronale sygdomme
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
EA199800818A1 (ru) Способ лечения бессонницы
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin
RU96118184A (ru) Способ лечения рефлекторных синдромов при остеохондрозе
DK1299102T3 (da) Anvendelse af riluzol eller salte deraf til forebyggelse og behandling af adrenoleukodystrofi